Researchers report the risk of death due to breast cancer could be reduced by about a third if patients are treated with a drug combination including Sanofi-Aventis' Taxotere along with adriamycin and cyclophosphamide. The scientists said a trial resulted in 90% of patients with a high risk of reoccurrence surviving for more than five years after treatment.

Full Story:

Related Summaries